{"title":"Weight Management","description":null,"products":[{"product_id":"retatrutide","title":"GLP-3 RT 20mg [Next-gen weight loss]","description":"\u003cp\u003e \u003c\/p\u003e\n\u003ch4\u003e\u003cstrong\u003eKey Health Benefits:\u003c\/strong\u003e\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003ch6\u003eSupports weight loss\u003c\/h6\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch6\u003eHelps preserve lean muscle\u003c\/h6\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch6\u003eReduce food cravings\u003c\/h6\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch6\u003eAids metabolic health\u003c\/h6\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch6\u003eLowers blood pressure\u003c\/h6\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch6\u003eImproves blood sugar control\u003c\/h6\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eOverview\u003cbr\u003eRetatrutide is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors — earning it the designation “GLP-3” for its triple-receptor mechanism. In Phase 2 clinical trials, Retatrutide produced the most significant weight loss results ever recorded for a pharmaceutical compound, with participants losing an average of 24% of their body weight over 48 weeks. It represents the cutting edge of metabolic and obesity research.\u003c\/p\u003e\n\u003cp\u003eMechanism of Action\u003cbr\u003eRetatrutide’s triple-receptor mechanism creates a powerful and synergistic metabolic effect. GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion. GIP receptor activation enhances insulin sensitivity and supports fat metabolism. Glucagon receptor activation drives hepatic fat oxidation and increases energy expenditure. The combination of all three pathways produces a degree of fat loss and metabolic improvement that surpasses any single or dual-agonist compound.\u003c\/p\u003e\n\u003cp\u003eResearch Applications\u003cbr\u003eResearch on Retatrutide has focused on obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular risk reduction. Phase 2 trial data has demonstrated unprecedented reductions in body weight, visceral fat, liver fat content, and cardiometabolic risk markers. It is currently considered the most promising next-generation weight loss compound in clinical development.\u003c\/p\u003e\n\u003cp\u003eReconstitution \u0026amp; Storage\u003cbr\u003eRetatrutide is supplied as a lyophilized powder. Reconstitute by adding bacteriostatic water slowly along the inner wall of the vial. Store unreconstituted vials away from direct light. Once reconstituted, keep refrigerated\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/Greyline_GLP3RT_Retatrutide_20mg_Guide.pdf?v=1779161236\"\u003eDownload Dosing Guide\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/videos\/c\/o\/v\/0958afeeddee437bb922f4b66d5a4be9.mov\"\u003eReconstitution Video\u003c\/a\u003e\u003c\/p\u003e","brand":"Greyline Peptides","offers":[{"title":"20mg","offer_id":43390387552330,"sku":"RETAT-20MG","price":160.0,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/IMG-3764.png?v=1776190802"},{"product_id":"tirzepatide","title":"Tirzepatide \/ GLP-2 (20mg) — Dual Agonist Fat Burner","description":"\u003cp\u003eOverview\u003cbr\u003eTirzepatide is a dual GLP-1\/GIP receptor agonist that has demonstrated remarkable efficacy in both type 2 diabetes management and weight loss in large-scale clinical trials. Marketed under the name Mounjaro for diabetes and Zepbound for obesity, it has become one of the most studied and clinically validated metabolic peptides in the world. For researchers studying fat metabolism, insulin resistance, and body composition, Tirzepatide offers a well-characterized and highly effective research tool.\u003c\/p\u003e\n\u003cp\u003eMechanism of Action\u003cbr\u003eTirzepatide simultaneously activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. GLP-1 activation suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. GIP activation enhances insulin sensitivity, promotes fat storage redistribution, and amplifies the GLP-1 response. Together, these mechanisms produce superior glycemic control and weight reduction compared to GLP-1 agonists alone.\u003c\/p\u003e\n\u003cp\u003eResearch Applications\u003cbr\u003eResearch on Tirzepatide has focused on type 2 diabetes management, obesity and weight reduction, non-alcoholic steatohepatitis (NASH), cardiovascular risk reduction, and polycystic ovary syndrome (PCOS). Phase 3 clinical trial data (SURMOUNT trials) demonstrated average weight loss of 20–22% of body weight, with significant improvements in blood pressure, lipid profiles, and glycemic markers.\u003c\/p\u003e\n\u003cp\u003eReconstitution \u0026amp; Storage\u003cbr\u003eTirzepatide is supplied as a lyophilized powder. Reconstitute by adding bacteriostatic water slowly along the inner wall of the vial. Store unreconstituted vials away from direct light. Once reconstituted, keep refrigerated.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/Greyline_GLP2TZ_Tirzepatide_20mg_Guide.pdf?v=1779161477\"\u003eDownload Dosing Guide\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/videos\/c\/o\/v\/0958afeeddee437bb922f4b66d5a4be9.mov\"\u003eReconstitution Video\u003c\/a\u003e\u003c\/p\u003e","brand":"Greyline Peptides","offers":[{"title":"20mg","offer_id":43390387781706,"sku":"TIRZ-20MG","price":160.0,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/IMG-4060.png?v=1776871797"},{"product_id":"glp-3-rt-30mg-next-gen-weight-loss-certificate-of-analysis-second-image-1","title":"GLP - 3 RT 30mg [next - gen weight loss]","description":"\u003cp\u003eOverview\u003cbr\u003eRetatrutide is a first-in-class triple agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors — earning it the designation “GLP-3” for its triple-receptor mechanism. In Phase 2 clinical trials, Retatrutide produced the most significant weight loss results ever recorded for a pharmaceutical compound, with participants losing an average of 24% of their body weight over 48 weeks. It represents the cutting edge of metabolic and obesity research.\u003c\/p\u003e\n\u003cp\u003eMechanism of Action\u003cbr\u003eRetatrutide’s triple-receptor mechanism creates a powerful and synergistic metabolic effect. GLP-1 receptor activation reduces appetite, slows gastric emptying, and improves insulin secretion. GIP receptor activation enhances insulin sensitivity and supports fat metabolism. Glucagon receptor activation drives hepatic fat oxidation and increases energy expenditure. The combination of all three pathways produces a degree of fat loss and metabolic improvement that surpasses any single or dual-agonist compound.\u003c\/p\u003e\n\u003cp\u003eResearch Applications\u003cbr\u003eResearch on Retatrutide has focused on obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), and cardiovascular risk reduction. Phase 2 trial data has demonstrated unprecedented reductions in body weight, visceral fat, liver fat content, and cardiometabolic risk markers. It is currently considered the most promising next-generation weight loss compound in clinical development.\u003c\/p\u003e\n\u003cp\u003eReconstitution \u0026amp; Storage\u003cbr\u003eRetatrutide is supplied as a lyophilized powder. Reconstitute by adding bacteriostatic water slowly along the inner wall of the vial. Store unreconstituted vials away from direct light. Once reconstituted, keep refrigerated.\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/Greyline_GLP3RT_Retatrutide_Guide.pdf?v=1779077453\"\u003eDownload Dosing Guide\u003c\/a\u003e \u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/videos\/c\/o\/v\/0958afeeddee437bb922f4b66d5a4be9.mov\"\u003eReconstitution Video\u003c\/a\u003e\u003c\/p\u003e","brand":"Greyline Peptides","offers":[{"title":"Default Title","offer_id":43423291637834,"sku":null,"price":225.0,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/24F0B15D-5D90-4453-9A6A-FB1EEB5BEB2C_d327713e-164e-4107-99e5-5b54b80a0cac.png?v=1773862966"},{"product_id":"glp-2-tz-30mg-dual-agonist-fat-burner","title":"Tirzepatide \/ GLP-2 (30mg) — Dual Agonist Fat Burner","description":"\u003cp\u003eOverview\u003cbr\u003eTirzepatide is a dual GLP-1\/GIP receptor agonist that has demonstrated remarkable efficacy in both type 2 diabetes management and weight loss in large-scale clinical trials. Marketed under the name Mounjaro for diabetes and Zepbound for obesity, it has become one of the most studied and clinically validated metabolic peptides in the world. For researchers studying fat metabolism, insulin resistance, and body composition, Tirzepatide offers a well-characterized and highly effective research tool.\u003c\/p\u003e\n\u003cp\u003eMechanism of Action\u003cbr\u003eTirzepatide simultaneously activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. GLP-1 activation suppresses appetite, slows gastric emptying, and stimulates glucose-dependent insulin secretion. GIP activation enhances insulin sensitivity, promotes fat storage redistribution, and amplifies the GLP-1 response. Together, these mechanisms produce superior glycemic control and weight reduction compared to GLP-1 agonists alone.\u003c\/p\u003e\n\u003cp\u003eResearch Applications\u003cbr\u003eResearch on Tirzepatide has focused on type 2 diabetes management, obesity and weight reduction, non-alcoholic steatohepatitis (NASH), cardiovascular risk reduction, and polycystic ovary syndrome (PCOS). Phase 3 clinical trial data (SURMOUNT trials) demonstrated average weight loss of 20–22% of body weight, with significant improvements in blood pressure, lipid profiles, and glycemic markers.\u003c\/p\u003e\n\u003cp\u003eReconstitution \u0026amp; Storage\u003cbr\u003eTirzepatide is supplied as a lyophilized powder. Reconstitute by adding bacteriostatic water slowly along the inner wall of the vial. Store unreconstituted vials away from direct light. Once reconstituted, keep refrigerated\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/Greyline_Tirzepatide_GLP2_30mg_Guide.pdf?v=1779509385\"\u003eDownload Dosing Guide\u003c\/a\u003e\u003c\/p\u003e\n\u003cp\u003e\u003ca href=\"https:\/\/cdn.shopify.com\/videos\/c\/o\/v\/0958afeeddee437bb922f4b66d5a4be9.mov\"\u003eReconstitution Video\u003c\/a\u003e\u003cbr\u003e\u003cspan\u003e\u003c\/span\u003e\u003c\/p\u003e","brand":"Greyline Peptides","offers":[{"title":"Default Title","offer_id":43448617992266,"sku":null,"price":225.0,"currency_code":"CAD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0698\/5983\/5978\/files\/IMG-3762.png?v=1776190310"}],"url":"https:\/\/greylinepeptides.com\/collections\/weight-management.oembed","provider":"Greyline","version":"1.0","type":"link"}